For-Robin
For-Robin
  • Home
  • About Us
  • Need/Opportunity
  • Technology
  • Publications
  • About Robin
  • Contact Us
  • More
    • Home
    • About Us
    • Need/Opportunity
    • Technology
    • Publications
    • About Robin
    • Contact Us

  • Home
  • About Us
  • Need/Opportunity
  • Technology
  • Publications
  • About Robin
  • Contact Us

Publications

 Ghazal D., Zalzala F., Fisk J. C., Tati S., Karacosta L. G., Morey S., Olson J. R., Quataert S., Dy G. K., Rittenhouse-Olson K. Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models. Oncotarget. 2022; 13: 1155-1164. Retrieved from https://www.oncotarget.com/article/28282/text/ 


Preclinical Analysis of JAA-F11, a Specific Anti–Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo  (2018)

http://www.transonc.com/article/S1936-5233(17)30300-5/fulltext


   Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype

Oncotarget. 2017; 8:98598-98608. https://doi.org/10.18632/oncotarget.21985  


 Jamie Heimburg-Molinaro, Michelle Lum, Geraldine Vijay, Adel Almogren and Kate Rittenhouse-Olson Cancer Vaccines and Carbohydrate Epitopes Vaccines(2011) doi:10.1016/j.vaccine.2011.09.009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208265/

  

Olga V. Glinskii, Virginia H. Huxley, Gennadi V. Glinsky, Kenneth J. Pienta, Avraham Raz, and Vladislav V. Glinsky: Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 7, 522-527 (2005).  doi:10.1593/neo.04646  

 Jamie Heimburg-Molinaro, Adel Almogren, Susan Morey, Olga V Glinskii, Rene Roy, Gregory E. Wilding, Richard P. Cheng, Vladislav V. Glinsky, and Kate Rittenhouse-Olson: Development, Characterization, and Immunotherapeutic Use of Peptide Mimics of the Thomsen-Friedenreich Carbohydrate Antigen.Neoplasia 11, 780–792 (2009) PMid:19649208 PMCid:2713588 


 Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In vitro Efficacy Analysis (2017)

https://www.ncbi.nlm.nih.gov/m/pubmed/28830009/?i=2&from=/29477636/related   https://authors.elsevier.com/sd/article/S1476558617302270



Adel Almogren, Julia Abdullah, Kshipra Ghapure, Kimiko Ferguson, Vladislav Glinskii, Kate Rittenhouse-Olson (2012). Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy. Frontiers in Bioscience.S4, 840-863.  http://www.bioscience.org/home/eoa/304.pdf 

 

Kimiko Ferguson, Arti Yadav, Susan Morey, Julia Abdullah, Gabriel Hrysenko, Jing Ying En, Munawwar Sajjad, Stephen Koury & Kate Rittenhouse-Olson (2014) Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer Future Oncology February 2014 ,Vol. 10, No. 3, Pages 385-399 , DOI 10.2217/fon.13.209 (doi:10.2217/fon.13.209)   https://www.futuremedicine.com/doi/10.2217/fon.13.209?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov& 

 Glinskii, O., Li, F., Wilson, L., Barnes, S., Rittenhouse-Olson, K., Barchi Jr, J., Pienta, K., & Glinsky, V. (2014). Endothelial integrin α3β1 stabilizes carbohydrate-mediated tumor/endothelial cell adhesion and induces macromolecular signaling complex formation at the endothelial cell membrane.Oncotarget, 5(5), 1382-1389. http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=1837


Matthew B. Tessier, Oliver C. Grant, Jamie Heimburg-Molinaro,Snehal Jadey, Andrew Gulick, Kate Rittenhouse-Olson, and Robert J. Woods. (2013) Computational Screening of the Human TF-Glycome Provides a Structural Definition for the Specificity of Anti-Tumor Antibody JAA-F11
PLoS ONE 8(1): e54874. doi:10.1371/journal.pone.0054874


 Peter Gassmann, Mi-Li Kang, Soeren T. Mees, and Joerg Haier: In vivo tumor cell adhesion in the pulmonary microvasculature is exclusively mediated by tumor cell--endothelial cell interaction. BMC Cancer 10, 177 (2010).  doi:10.1186/1471-2407-10-177 

https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-177


  Olga V. Glinskii, James R. Turk, Kenneth J. Pienta, Virginia H. Huxley, and Vladislav V. Glinsky: Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells. J Physiol554, 89-99 (2004)  doi:10.1113/jphysiol.2003.054783
 

Richa Chaturvedi, Jamie Heimburg., Jun Yan, Stephen Koury, Munwwar Sujjad, hani H. Abdel Nabi, Kate Rittenhouse-Olson: Tumor immunolocalization using 124-Iodine labeled JAA-F11antibody to Thomsen Friedenreich alpha-linked antigen. Applied Radiations and isotopes 66, 278-287 (2008) doi:10.1016/j.apradiso.2007.07.029 



  Rittenhouse-Olson, K. Future Perspective article. JAA-F11: Extending the life of mice with breast cancer. In p.923-927. Expert Opinions in Biological Therapy 7 (7) 2007.  


Jamie Heimburg, Jun Yan, Susan Morey, Olga V. Glinskii, Virginia H. Huxley, Linda Wild, Robert Klick, Rene Roy, Vladislav V. Glinsky, and Kate Rittenhouse-Olson: Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11 Neoplasia 8, 939-948 (2006).  doi:10.1593/neo.06493



  

V. V. Glinsky, G. V. Glinsky, K. Rittenhouse-Olson, M. E. Huflejt, O. V. Glinskii, S. L. Deutscher, and T. P. Quinn: The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61, 4851-4857 (2001).PMid:11406562

http://cancerres.aacrjournals.org/content/61/12/4851.long


K. Rittenhouse-Diakun, Z. Xia, D. Pickhardt, S. Morey, M. G. Baek, and R. Roy: Development and characterization of monoclonal antibody to T-antigen: (Gal beta1-3GalNAc-alpha-O). Hybridoma 17, 165-173 (1998).  doi:10.1089/hyb.1998.17.165 




Protective Effect of Naturally Occurring Antibodies to TF-Ag

Kodar, K., O. Kurtenkov, and K. Klaamas: The Thomsen-Friedenreich antigen and alpha gal-specific human IgG glycoforms: concanavalin a reactivity and relation to survival of cancer patients. Immunol Invest 38, 704-17 (2009). 
doi:10.3109/08820130903147193 PMid:19860583



O. Kurtenkov, K. Klaamas, S. Mensdorff-Pouilly, L. Miljukhina, L. Shljapnikova, and V. Chuzmarov: Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 46, 316-323 (2007).
doi:10.1080/02841860601055441

E. P. Smorodin, O. A. Kurtenkov, B. L. Sergeyev, V. I. Chuzmarov, and V. P. Afanasyev: The relation of serum anti-(GalNAc beta) and -para-Forssman disaccharide IgG levels to the progression and histological grading of gastrointestinal cancer. Exp Oncol 29, 61-66 (2007).



 Klaamas, K., Kurtenkov, O., Rittenhouse-Olson, K., Brjalin, V., Miljukhina, L., Shljapnikova, L., Engstrand, L: Expression of tumor-associated Thomsen-Friedenreich Antigen (T Ag) in Helicobacter pylori and modulation of T Ag specific immune response in infected individuals.Immunol Invest 31, 191-204 (2002). 
doi:10.1081/IMM-120016240 PMid:12472179

P. R. Desai Immunoreactive T and Tn antigens in malignancy: role in carcinoma diagnosis, prognosis, and immunotherapy. Transfus Med Rev. (4):312-25 (2000). 
doi:10.1053/tmrv.2000.16229 PMid:11055076





G. F. Springer, S. M. Murthy, P. R. Desai, W. A. Fry, H. Tegtmeyer, and E. F. Scanlon: Patients' immune response to breast and lung carcinoma-associated Thomsen-Friedenreich (T) specificity. Klin Wochenschr 60, 121-131 (1982).
doi:10.1007/BF01711276

G. F. Springer, M. S. Murthy, P. R. Desai, and E. F. Scanlon: Breast cancer patient's cell-mediated immune response to Thomsen-Friedenreich (T) antigen.Cancer 45, 2949-2954 (1980) 
doi:10.1002/1097-0142(19800615)45:12<2949::AID-CNCR2820451210>3.0.CO;2-L



 Kurtenkov, L. Miljukhina, J. Smorodin, K. Klaamas, N. Bovin, M. Ellamaa, and V. Chuzmarov: Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors--relation to Lewis (a,b) histo-blood group phenotype. Acta Oncol38, 939-943 (1999).
doi:10.1080/028418699432626

G. F. Springer: Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med75, 594-602 (1997).
doi:10.1007/s001090050144 PMid:9297627




Georg F. Springer, Parimal R. Desai, Herta Tegtmeyer, Bruce D. Spencer, and Edward F. Scanlon: Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast carcinoma recurrence. Ann NY Acad Sci 690, 355-357 (1993)doi:10.1111/j.1749-6632.1993.tb44029.x PMid:8368754

G. F. Springer, P. R. Desai, and E. F. Scanlon: Blood group MN precursors as human breast carcinoma-associated antigens and "naturally" occurring human cytotoxins against them. Cancer37, 169-176 (1976). 
doi:10.1002/1097-0142(197601)37:1<169::AID-CNCR2820370124>3.0.CO;2-#

Copyright © 2022 For-Robin - All Rights Reserved.

Powered by GoDaddy